{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,20]],"date-time":"2026-10-20T16:07:26Z","timestamp":1792512446593,"version":"4.5.0"},"reference-count":23,"publisher":"Springer Science and Business Media LLC","issue":"12","license":[{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T00:00:00Z","timestamp":1761696000000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Int J Clin Oncol"],"published-print":{"date-parts":[[2025,12]]},"DOI":"10.1007\/s10147-025-02909-9","type":"journal-article","created":{"date-parts":[[2025,10,29]],"date-time":"2025-10-29T12:27:15Z","timestamp":1761740835000},"page":"2587-2595","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["Elevated proportion of eosinophils predicts immune-related adverse events and improved survival in patients with gastric cancer treated with nivolumab"],"prefix":"10.1007","volume":"30","author":[{"given":"Sohei","family":"Matsumoto","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hiroshi","family":"Nakade","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Tomohiro","family":"Kunishige","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Shintaro","family":"Miyao","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Satoko","family":"Aoki","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Akinori","family":"Tsujimoto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Takanari","family":"Tatsumi","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masahiro","family":"Soga","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Masayuki","family":"Sho","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2025,10,29]]},"reference":[{"key":"2909_CR1","doi-asserted-by":"publisher","DOI":"10.1016\/j.eclinm.2022.101404","volume":"47","author":"E Morgan","year":"2022","unstructured":"Morgan E, Arnold M, Camargo MC et al (2022) The current and future incidence and mortality of gastric cancer in 185 countries, 2020\u201340: a population-based modelling study. EClinicalMedicine 47:101404. https:\/\/doi.org\/10.1016\/j.eclinm.2022.101404","journal-title":"EClinicalMedicine"},{"key":"2909_CR2","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/S1470-2045(08)70035-4","volume":"9","author":"W Koizumi","year":"2008","unstructured":"Koizumi W, Narahara H, Hara T et al (2008) S-1 plus cisplatin versus S-1 alone for first-line treatment of advanced gastric cancer (SPIRITS trial): a phase III trial. Lancet Oncol 9:215\u2013221. https:\/\/doi.org\/10.1016\/S1470-2045(08)70035-4","journal-title":"Lancet Oncol"},{"key":"2909_CR3","doi-asserted-by":"publisher","first-page":"141","DOI":"10.1093\/annonc\/mdu472","volume":"26","author":"Y Yamada","year":"2015","unstructured":"Yamada Y, Higuchi K, Nishikawa K et al (2015) Phase III study comparing oxaliplatin plus S-1 with cisplatin plus S-1 in chemotherapy-naive patients with advanced gastric cancer. Ann Oncol 26:141\u2013148. https:\/\/doi.org\/10.1093\/annonc\/mdu472","journal-title":"Ann Oncol"},{"key":"2909_CR4","doi-asserted-by":"publisher","first-page":"2461","DOI":"10.1016\/S0140-6736(17)31827-5","volume":"390","author":"YK Kang","year":"2017","unstructured":"Kang YK, Boku N, Satoh T et al (2017) Nivolumab in patients with advanced gastric or gastro-oesophageal junction cancer refractory to, or intolerant of, at least two previous chemotherapy regimens (ONO-4538-12, ATTRACTION-2): a randomised, double-blind, placebo-controlled, phase 3 trial. Lancet 390:2461\u20132471. https:\/\/doi.org\/10.1016\/S0140-6736(17)31827-5","journal-title":"Lancet"},{"key":"2909_CR5","doi-asserted-by":"publisher","first-page":"234","DOI":"10.1016\/S1470-2045(21)00692-6","volume":"23","author":"YK Kang","year":"2022","unstructured":"Kang YK, Chen LT, Ryu MH et al (2022) Nivolumab plus chemotherapy versus placebo plus chemotherapy in patients with HER2-negative, untreated, unresectable advanced or recurrent gastric or gastro-oesophageal junction cancer (ATTRACTION-4): a randomised, multicentre, double-blind, placebo-controlled, phase 3 trial. Lancet Oncol 23:234\u2013247. https:\/\/doi.org\/10.1016\/S1470-2045(21)00692-6","journal-title":"Lancet Oncol"},{"key":"2909_CR6","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1016\/S0140-6736(21)00797-2","volume":"398","author":"YY Janjigian","year":"2021","unstructured":"Janjigian YY, Shitara K, Moehler M et al (2021) First-line nivolumab plus chemotherapy versus chemotherapy alone for advanced gastric, gastro-oesophageal junction, and oesophageal adenocarcinoma (CheckMate 649): a randomised, open-label, phase 3 trial. Lancet 398:27\u201340. https:\/\/doi.org\/10.1016\/S0140-6736(21)00797-2","journal-title":"Lancet"},{"key":"2909_CR7","doi-asserted-by":"publisher","first-page":"3189","DOI":"10.1007\/s10238-023-01104-2","volume":"23","author":"X Xu","year":"2023","unstructured":"Xu X, Chen J, Li W et al (2023) Immunology and immunotherapy in gastric cancer. Clin Exp Med 23:3189\u20133204. https:\/\/doi.org\/10.1007\/s10238-023-01104-2","journal-title":"Clin Exp Med"},{"key":"2909_CR8","doi-asserted-by":"publisher","first-page":"107327482199743","DOI":"10.1177\/1073274821997430","volume":"28","author":"K Chen","year":"2021","unstructured":"Chen K, Wang X, Yang L et al (2021) The anti-PD-1\/PD-L1 immunotherapy for gastric esophageal cancer: a systematic review and meta-analysis and literature review. Cancer Control 28:1073274821997430. https:\/\/doi.org\/10.1177\/1073274821997430","journal-title":"Cancer Control"},{"key":"2909_CR9","doi-asserted-by":"publisher","first-page":"1408755","DOI":"10.3389\/fonc.2024.1408755","volume":"14","author":"YJ Zhang","year":"2024","unstructured":"Zhang YJ, Tian QY, Wang CE (2024) Association between immune-related adverse events and the prognosis of patients with gastric cancer treated with nivolumab: a meta-analysis. Front Oncol 14:1408755. https:\/\/doi.org\/10.3389\/fonc.2024.1408755","journal-title":"Front Oncol"},{"key":"2909_CR10","doi-asserted-by":"publisher","first-page":"21666","DOI":"10.1002\/cam4.6724","volume":"12","author":"Y Tasaki","year":"2023","unstructured":"Tasaki Y, Sugiyama Y, Hamamoto S et al (2023) Eosinophil may be a predictor of immune-related adverse events induced by different immune checkpoint inhibitor types: a retrospective multidisciplinary study. Cancer Med 12:21666\u201321679. https:\/\/doi.org\/10.1002\/cam4.6724","journal-title":"Cancer Med"},{"key":"2909_CR11","doi-asserted-by":"publisher","first-page":"492","DOI":"10.1186\/s40001-023-01365-3","volume":"28","author":"P Ding","year":"2023","unstructured":"Ding P, Liu P, Meng L et al (2023) Mechanisms and biomarkers of immune-related adverse events in gastric cancer. Eur J Med Res 28:492. https:\/\/doi.org\/10.1186\/s40001-023-01365-3","journal-title":"Eur J Med Res"},{"key":"2909_CR12","doi-asserted-by":"publisher","first-page":"1118","DOI":"10.20892\/j.issn.2095-3941.2021.0052","volume":"18","author":"R Bai","year":"2021","unstructured":"Bai R, Chen N, Chen X et al (2021) Analysis of characteristics and predictive factors of immune checkpoint inhibitor-related adverse events. Cancer Biol Med 18:1118\u20131133. https:\/\/doi.org\/10.20892\/j.issn.2095-3941.2021.0052","journal-title":"Cancer Biol Med"},{"key":"2909_CR13","doi-asserted-by":"publisher","first-page":"228","DOI":"10.1016\/j.ejca.2008.10.026","volume":"45","author":"EA Eisenhauer","year":"2009","unstructured":"Eisenhauer EA, Therasse P, Bogaerts J et al (2009) New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer 45:228\u2013247. https:\/\/doi.org\/10.1016\/j.ejca.2008.10.026","journal-title":"Eur J Cancer"},{"key":"2909_CR14","doi-asserted-by":"publisher","first-page":"iv119","DOI":"10.1093\/annonc\/mdx225","volume":"28","author":"J Haanen","year":"2017","unstructured":"Haanen J, Carbonnel F, Robert C et al (2017) Management of toxicities from immunotherapy: ESMO clinical practice guidelines for diagnosis, treatment and follow-up. Ann Oncol 28:iv119\u2013iv142. https:\/\/doi.org\/10.1093\/annonc\/mdx225","journal-title":"Ann Oncol"},{"key":"2909_CR15","doi-asserted-by":"publisher","DOI":"10.1016\/j.clgc.2024.102099","volume":"22","author":"E Gambale","year":"2024","unstructured":"Gambale E, Maruzzo M, Messina C et al (2024) Neutrophil-to-eosinophil ratio predicts the efficacy of avelumab in patients with advanced urothelial carcinoma enrolled in the MALVA study (Meet-URO 25). Clin Genitourin Cancer 22:102099. https:\/\/doi.org\/10.1016\/j.clgc.2024.102099","journal-title":"Clin Genitourin Cancer"},{"key":"2909_CR16","doi-asserted-by":"publisher","first-page":"248","DOI":"10.1111\/1759-7714.15191","volume":"15","author":"E Takeuchi","year":"2024","unstructured":"Takeuchi E, Ogino H, Kondo K et al (2024) An increased relative eosinophil count as a predictive dynamic biomarker in non-small cell lung cancer patients treated with immune checkpoint inhibitors. Thorac Cancer 15:248\u2013257. https:\/\/doi.org\/10.1111\/1759-7714.15191","journal-title":"Thorac Cancer"},{"key":"2909_CR17","doi-asserted-by":"publisher","first-page":"2694","DOI":"10.1016\/j.mayocp.2021.04.025","volume":"96","author":"ME Wechsler","year":"2021","unstructured":"Wechsler ME, Munitz A, Ackerman SJ et al (2021) Eosinophils in health and disease: a state-of-the-art review. Mayo Clin Proc 96:2694\u20132707. https:\/\/doi.org\/10.1016\/j.mayocp.2021.04.025","journal-title":"Mayo Clin Proc"},{"issue":"106\u2013123","key":"2909_CR18","doi-asserted-by":"publisher","DOI":"10.1016\/j.ccell.2022.11.014","volume":"41","author":"OS Blomberg","year":"2023","unstructured":"Blomberg OS, Spagnuolo L, Garner H et al (2023) IL-5-producing CD4(+) T cells and eosinophils cooperate to enhance response to immune checkpoint blockade in breast cancer. Cancer Cell 41(106\u2013123):e110. https:\/\/doi.org\/10.1016\/j.ccell.2022.11.014","journal-title":"Cancer Cell"},{"key":"2909_CR19","doi-asserted-by":"publisher","first-page":"1641","DOI":"10.2147\/CMAR.S360473","volume":"14","author":"N Furubayashi","year":"2022","unstructured":"Furubayashi N, Minato A, Negishi T et al (2022) Association between immune-related adverse events and efficacy and changes in the relative eosinophil count among patients with advanced urothelial carcinoma treated by pembrolizumab. Cancer Manag Res 14:1641\u20131651. https:\/\/doi.org\/10.2147\/CMAR.S360473","journal-title":"Cancer Manag Res"},{"key":"2909_CR20","doi-asserted-by":"publisher","first-page":"594","DOI":"10.1038\/s41568-020-0283-9","volume":"20","author":"S Grisaru-Tal","year":"2020","unstructured":"Grisaru-Tal S, Itan M, Klion AD et al (2020) A new dawn for eosinophils in the tumour microenvironment. Nat Rev Cancer 20:594\u2013607. https:\/\/doi.org\/10.1038\/s41568-020-0283-9","journal-title":"Nat Rev Cancer"},{"key":"2909_CR21","doi-asserted-by":"publisher","first-page":"76","DOI":"10.1016\/j.lungcan.2020.08.015","volume":"150","author":"X Chu","year":"2020","unstructured":"Chu X, Zhao J, Zhou J et al (2020) Association of baseline peripheral-blood eosinophil count with immune checkpoint inhibitor-related pneumonitis and clinical outcomes in patients with non-small cell lung cancer receiving immune checkpoint inhibitors. Lung Cancer 150:76\u201382. https:\/\/doi.org\/10.1016\/j.lungcan.2020.08.015","journal-title":"Lung Cancer"},{"key":"2909_CR22","doi-asserted-by":"publisher","first-page":"527","DOI":"10.1001\/jamaoncol.2022.7711","volume":"9","author":"MA Socinski","year":"2023","unstructured":"Socinski MA, Jotte RM, Cappuzzo F et al (2023) Association of immune-related adverse events with efficacy of atezolizumab in patients with non-small cell lung cancer: pooled analyses of the Phase 3 IMpower130, IMpower132, and IMpower150 randomized clinical trials. JAMA Oncol 9:527\u2013535. https:\/\/doi.org\/10.1001\/jamaoncol.2022.7711","journal-title":"JAMA Oncol"},{"key":"2909_CR23","doi-asserted-by":"publisher","first-page":"1483956","DOI":"10.3389\/fimmu.2024.1483956","volume":"15","author":"Y Tasaki","year":"2024","unstructured":"Tasaki Y, Hamamoto S, Yamashita S et al (2024) Eosinophil is a predictor of severe immune-related adverse events induced by ipilimumab plus nivolumab therapy in patients with renal cell carcinoma: a retrospective multicenter cohort study. Front Immunol 15:1483956. https:\/\/doi.org\/10.3389\/fimmu.2024.1483956","journal-title":"Front Immunol"}],"container-title":["International Journal of Clinical Oncology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02909-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10147-025-02909-9\/fulltext.html","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10147-025-02909-9.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,11,24]],"date-time":"2025-11-24T22:02:30Z","timestamp":1764021750000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10147-025-02909-9"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2025,10,29]]},"references-count":23,"journal-issue":{"issue":"12","published-print":{"date-parts":[[2025,12]]}},"alternative-id":["2909"],"URL":"https:\/\/doi.org\/10.1007\/s10147-025-02909-9","relation":{},"ISSN":["1341-9625","1437-7772"],"issn-type":[{"value":"1341-9625","type":"print"},{"value":"1437-7772","type":"electronic"}],"subject":[],"published":{"date-parts":[[2025,10,29]]},"assertion":[{"value":"30 June 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 October 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"29 October 2025","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare no conflicts of interest.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}},{"value":"All procedures performed in this study involving human participants were in accordance with the ethical standards of the institutional and\/or national research committee and with the 1964 Helsinki Declaration and its later amendments or comparable ethical standards. This retrospective study was approved by the Nara Medical University Hospital Institutional Review Board (no. 3280).","order":3,"name":"Ethics","group":{"name":"EthicsHeading","label":"Ethical approval"}},{"value":"We conducted a retrospective study and used the \u201copt-out\u201d method as a way to obtain informed consent from patients.","order":4,"name":"Ethics","group":{"name":"EthicsHeading","label":"Consent to participate"}}]}}